Keros Therapeutics, Inc. Operating Expenses
Keros Therapeutics, Inc. (KROS) reported Operating Expenses of $30.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-03
- Keros Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $30.94M, a 46.65% decline year-over-year.
- Keros Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $26.24M, a 55.67% decline year-over-year.
- Keros Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $29.66M, a 47.32% decline year-over-year.
- Keros Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $29.65M, a 49.79% decline year-over-year.
- Keros Therapeutics, Inc. operating expenses for fiscal 2025 was $176.49M, a 17.67% decline from fiscal 2024.
- Keros Therapeutics, Inc. operating expenses for fiscal 2024 was $214.38M, a 26.04% increase from fiscal 2023.
- Keros Therapeutics, Inc. operating expenses for fiscal 2023 was $170.09M, a 48.18% increase from fiscal 2022.
- Keros Therapeutics, Inc. operating expenses for fiscal 2022 was $114.79M, a 50.11% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.94M 10-Q · filed 2026-08-03 | $57.18M 10-Q · filed 2026-08-03 | $86.84M derived: sum of 3 quarters · filed 2026-08-03 | $116.48M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $26.24M 10-Q · filed 2026-05-14 | $55.90M derived: sum of 2 quarters · filed 2026-05-14 | $85.55M derived: sum of 3 quarters · filed 2026-05-14 | $143.53M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $29.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $59.30M derived: sum of 2 quarters · filed 2026-03-04 | $117.29M derived: sum of 3 quarters · filed 2026-08-03 | $176.49M 10-K · filed 2026-03-04 |
| 2025-09-30 | $29.65M 10-Q · filed 2025-11-05 | $87.63M derived: sum of 2 quarters · filed 2026-08-03 | $146.84M 10-Q · filed 2025-11-05 | $203.13M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $57.98M 10-Q · filed 2026-08-03 | $117.19M 10-Q · filed 2026-08-03 | $173.49M derived: sum of 3 quarters · filed 2026-08-03 | $232.53M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $59.21M 10-Q · filed 2026-05-14 | $115.50M derived: sum of 2 quarters · filed 2026-05-14 | $174.55M derived: sum of 3 quarters · filed 2026-05-14 | $225.02M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $56.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $115.34M derived: sum of 2 quarters · filed 2026-03-04 | $165.82M derived: sum of 3 quarters · filed 2026-03-04 | $214.38M 10-K · filed 2026-03-04 |
| 2024-09-30 | $59.05M 10-Q · filed 2025-11-05 | $109.52M derived: sum of 2 quarters · filed 2025-11-05 | $158.09M 10-Q · filed 2025-11-05 | $204.69M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $50.48M 10-Q · filed 2025-08-06 | $99.04M 10-Q · filed 2025-08-06 | $145.64M derived: sum of 3 quarters · filed 2025-08-06 | $188.93M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $48.57M 10-Q · filed 2025-05-06 | $95.16M derived: sum of 2 quarters · filed 2025-05-06 | $138.45M derived: sum of 3 quarters · filed 2025-05-06 | $179.79M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $46.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $89.89M derived: sum of 2 quarters · filed 2025-02-26 | $131.22M derived: sum of 3 quarters · filed 2025-02-26 | $170.09M 10-K · filed 2025-02-26 |
| 2023-09-30 | $43.29M 10-Q · filed 2024-11-06 | $84.63M derived: sum of 2 quarters · filed 2024-11-06 | $123.49M 10-Q · filed 2024-11-06 | $155.45M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $41.34M 10-Q · filed 2024-08-07 | $80.21M 10-Q · filed 2024-08-07 | $112.17M derived: sum of 3 quarters · filed 2025-02-26 | $140.14M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $38.87M 10-Q · filed 2024-05-08 | $70.83M derived: sum of 2 quarters · filed 2025-02-26 | $98.81M derived: sum of 3 quarters · filed 2025-02-26 | $129.53M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $31.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $59.94M derived: sum of 2 quarters · filed 2025-02-26 | $90.66M derived: sum of 3 quarters · filed 2025-02-26 | $114.79M 10-K · filed 2025-02-26 |
| 2022-09-30 | $27.98M 10-Q · filed 2023-11-06 | $58.70M derived: sum of 2 quarters · filed 2023-11-06 | $82.83M 10-Q · filed 2023-11-06 | $107.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $30.73M 10-Q · filed 2023-08-07 | $54.85M 10-Q · filed 2023-08-07 | $79.72M derived: sum of 3 quarters · filed 2024-02-28 | $99.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $24.13M 10-Q · filed 2023-05-04 | $48.99M derived: sum of 2 quarters · filed 2024-02-28 | $69.19M derived: sum of 3 quarters · filed 2024-02-28 | $84.83M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $24.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $45.06M derived: sum of 2 quarters · filed 2024-02-28 | $60.70M derived: sum of 3 quarters · filed 2024-02-28 | $76.47M 10-K · filed 2024-02-28 |
| 2021-09-30 | $20.20M 10-Q · filed 2022-11-03 | $35.84M derived: sum of 2 quarters · filed 2022-11-03 | $51.61M 10-Q · filed 2022-11-03 | $64.90M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $15.64M 10-Q · filed 2022-08-04 | $31.41M 10-Q · filed 2022-08-04 | $44.70M derived: sum of 3 quarters · filed 2022-08-04 | $56.65M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $15.77M 10-Q · filed 2022-05-05 | $29.06M derived: sum of 2 quarters · filed 2022-05-05 | $41.01M derived: sum of 3 quarters · filed 2022-05-05 | $51.92M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $13.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $25.24M derived: sum of 2 quarters · filed 2022-03-09 | $36.15M derived: sum of 3 quarters · filed 2022-03-09 | $46.66M 10-K · filed 2022-03-09 |
| 2020-09-30 | $11.95M 10-Q · filed 2021-11-04 | $22.86M derived: sum of 2 quarters · filed 2021-11-04 | $33.37M 10-Q · filed 2021-11-04 | $38.59M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $10.91M 10-Q · filed 2021-08-05 | $21.42M 10-Q · filed 2021-08-05 | $26.65M derived: sum of 3 quarters · filed 2021-08-05 | $31.47M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $10.50M 10-Q · filed 2021-05-06 | $15.73M derived: sum of 2 quarters · filed 2021-05-06 | $20.56M derived: sum of 3 quarters · filed 2021-05-06 | $25.71M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $5.23M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $10.05M derived: sum of 2 quarters · filed 2021-03-25 | $15.21M derived: sum of 3 quarters · filed 2021-03-25 | $20.56M 10-K · filed 2021-03-25 |
| 2019-09-30 | $4.83M 10-Q · filed 2020-11-10 | $9.98M derived: sum of 2 quarters · filed 2020-11-10 | $15.34M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $5.15M 10-Q · filed 2020-08-13 | $10.51M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $5.36M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |